The US Supreme Court in a landmark decision held that a DNA molecule is potentially eligible for patenting in the US if its sequence does not occur in nature, but is not patent-eligible if its sequence is identical to a naturally occurring DNA sequence.
BerGenBio’s ‘ask the cell’ technology could potentially change cancer treatment as we know it. With an expanding patent portfolio and library of trade secrets behind it, what challenges does the startup biotech company face in bringing its first drugs to market?
The definition of what constitutes a co-pending patent filing in Europe has recently been rewritten to include patent applications from within the same patent family. Jane Wainwright of Potter Clarkson investigates the decisions leading to this change.
While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges.
James Monroe and Lawrence Ilag of Finnegan, Henderson, Farabow, Garrett & Dunner LLP analyse the impact of the US Court of Appeals for the Federal Circuit’s decision In re Kubin.
Patent term restoration has been adopted by several jurisdictions, with varying success. Mexico faces several issues with sanitary authorisations and patent examination, so patent term restoration would be a viable remedy for patent holders. The TPP might enable this.
To read much of the reaction to recent pharmaceutical rulings in India, you might think that the country is waging a war against Western innovation. But while there is certainly cause for concern, that’s not the whole story, as LSIPR finds out.
There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain.
The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system.
In its effort to tackle the threat of ‘evergreening’, the CJEU has caused some uncertainty about supplementary protection certificates, as Jaap Mannaerts explains.